Research focus


Concentrates of plasma factors such as factor VIII and factor IX for the treatment of bleeding diseases have for many years been one of Biotest’s mainstays. Constant improvement and further clinical development of our licensed products plus expansion of the range of clotting factors are a special area of interest in haematology.

Biotest is engaged in the development of an innovative recombinant factor VIII preparation for the treatment of haemophilia A: 
Haemophilia A Therapeutic (HAT)
The compound is characterised by a significantly extended half-life with the option of intravenous or subcutaneous application. In addition, the molecule is designed to reduce the risk of inhibitor formation.  The project is in the preclinical phase.

Latest publication of ISTH 2020

Poster ISTH 2020



A Novel Coagulation Factor VIII with Reduced Immunogenicity A
PDF, 1.01 MB
[ Download ]


Raising Factor VIII’s Half-Life to the Next Level
PDF, 1.02 MB
[ Download ]


A Next Generation Recombinant Factor VIII for Subcutaneous Hemophilia A Prophylaxis
PDF, 979 KB
[ Download ]

Presentation ISTH 2020

At the ISTH 2020 Biotest presented its novel recombinant Factor VIII molecules overcoming the major challenges of current Factor VIII replacement therapy by combining  a significantly extended half-life, low immunogenicity and the possibility of either subcutaneous or intravenous administration.